Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9801818rdf:typepubmed:Citationlld:pubmed
pubmed-article:9801818lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:9801818lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:9801818lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:9801818lifeskim:mentionsumls-concept:C0443288lld:lifeskim
pubmed-article:9801818lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:9801818lifeskim:mentionsumls-concept:C0337112lld:lifeskim
pubmed-article:9801818pubmed:issue9lld:pubmed
pubmed-article:9801818pubmed:dateCreated1999-1-12lld:pubmed
pubmed-article:9801818pubmed:abstractTextA number of sulfonic acid ester derivatives of serotonin (5-hydroxytryptamine; 5-HT; 1) were prepared and their affinities are compared to that of the reference compound 5-[[(trifluoromethyl)sulfonyl]oxy]-tryptamine (8b). The structure-affinity relationship (SAFIR) is discussed in terms of in vitro binding for cloned human h5-HT1A, h5-HT1B and h5-HT1D receptors. All tryptamine derivatives exhibited the best affinities for h5-HT1D receptors but still, these were comparatively lower than that of compound 8b. 5-Tosylated tryptamine 11b (Ki = 6 nM) and the sulfamate derivatives 13b and 14b (Ki = 7 and 11 nM, respectively) were found to have the highest affinities for the h5-HT1D receptor. Other tryptamine derivatives displayed moderate binding for h5-HT1A and h5-HT1B receptors, along with Ki values ranging from 14-20 nM for the h5-HT1D sites. In addition, the syntheses of two alkylamino side chain restricted derivatives are described. 3-Amino-6-[[(trifluoromethyl)sulfonyl]oxy]-1,2,3,4-tetrahydrocarbazol e 21, as well as 4-[5-[[(trifluoromethyl)sulfonyl]oxy]-1H-indol-3-yl]piperidines 24 and 25, induced a shift in selectivity in favor of the h5-HT1B receptor. The relatively longer distance between the basic amine and a hydrogen-bond accepting oxygen in 21, 24 and 25 as compared to the non-restricted tryptamines, is likely responsible for this observation.lld:pubmed
pubmed-article:9801818pubmed:languageenglld:pubmed
pubmed-article:9801818pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:citationSubsetIMlld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9801818pubmed:statusMEDLINElld:pubmed
pubmed-article:9801818pubmed:monthSeplld:pubmed
pubmed-article:9801818pubmed:issn0968-0896lld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:WikströmHHlld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:SundellSSlld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:PauwelsP JPJlld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:PalmierCClld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:LundmarkMMlld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:BargSSlld:pubmed
pubmed-article:9801818pubmed:authorpubmed-author:TardifSSlld:pubmed
pubmed-article:9801818pubmed:issnTypePrintlld:pubmed
pubmed-article:9801818pubmed:volume6lld:pubmed
pubmed-article:9801818pubmed:ownerNLMlld:pubmed
pubmed-article:9801818pubmed:authorsCompleteYlld:pubmed
pubmed-article:9801818pubmed:pagination1469-79lld:pubmed
pubmed-article:9801818pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:meshHeadingpubmed-meshheading:9801818-...lld:pubmed
pubmed-article:9801818pubmed:year1998lld:pubmed
pubmed-article:9801818pubmed:articleTitle5-(Sulfonyl)oxy-tryptamines and ethylamino side chain restricted derivatives. Structure-affinity relationships for h5-HT1B and h5-HT1D receptors.lld:pubmed
pubmed-article:9801818pubmed:affiliationDepartment of Medicinal Chemistry, University of Groningen, The Netherlands. tjeerd.barf@eu.pnu.comlld:pubmed
pubmed-article:9801818pubmed:publicationTypeJournal Articlelld:pubmed